Important Notice Please note our hours are Mon - Sat 8am-3pm & Sun 9am-4pm. Our address is 9390 Huebner Rd #104, San Antonio, TX 78240. We will post updates on our Facebook Page. Tyme Technologies, Inc., is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles.
BEDMINSTER, N.J.--(BUSINESS WIRE)--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTsTM), announced that the final results of its SM-88 Phase II Prostate Cancer study designed to evaluate the safety, tolerability and efficacy of SM-88 in patients with non-metastatic biochemical recurrent prostate cancer, was published on September 13th, 2020 in the peer-reviewed journal Investigational New Drugs. The article, titled “Phase II Trial of SM-88, a Cancer Metabolism Based Therapy, in Non-Metastatic Biochemical Recurrent Prostate Cancer,” is available online at https://doi.org/10.1007/s10637-020-00993-4.
The study demonstrated that SM-88 had promising efficacy and safety outcomes for prostate cancer patients while sparing testosterone. The study also demonstrated a reduction of CTCs, an important prognostic indicator, that may prove to be a better surrogate for patient outcomes than PSA, particularly for SM-88.
“Oral SM-88 has demonstrated potential efficacy and a well-tolerated safety profile that may represent a new treatment option for more than 450,000 prostate cancer patients in the U.S. alone seeking a non-cytotoxic, non-hormonal therapy,” said Giuseppe Del Priore, M.D., M.P.H., Chief Medical Officer at TYME. “We are encouraged by the clinical results of our unique proprietary approach using cancer metabolism-based therapies that we believe attack the cancer cells from within, interrupting the cancer metabolic processes.”
From September 2016 to April 2019, twenty-three evaluable patients with non-metastatic pancreatic cancer with rising PSA levels, detectable circulating tumor cells and no radiographically detectable metastases were assessed in a Phase II trial. All patients received 230 mgs twice per day of SM-88 orally. Patients also received oral doses of methoxsalen (10 mg), phenytoin (50 mg), and sirolimus (0.5 mg) once per day. Most patients had previously received androgen-deprivation therapy (ADT) after radiation therapy or surgery, but ADT treatment changes were not permitted during the trial.
From the initial diagnoses of PSA rise, 100% of patients (23/23) remained free of metastatic progression (MFS) and 87% of patients (20/23) have maintained radiographic progression-free survival (rPFS) with a median duration of therapy of 6.5 months since starting SM-88 treatment. All patients who have maintained meaningful reductions in circulating tumor cells (CTCs) on SM-88 were 100% free of any radiographic progression.
At baseline, the median PSA for patients with radiographic progression was 13.4 compared to 5.6 for patients with no radiographic progression (p=0.02). Among evaluable patients, PSA stabilized in 83% of patients (19/23). Importantly, 52% of evaluable patients (12/23) experienced an improvement in median PSA doubling time (DT), a positive prognostic indicator. In all patients who completed three cycles of therapy, the median DT improved nearly 34.4% from 6.1 to 8.2 months (n=20). After 12 weeks, or three cycles of therapy, 78.2% of patients (18/23) demonstrated a decrease in CTC from baseline, with a median decrease of 65.3%.
Patients without local progression (20/23) had slightly higher testosterone levels at baseline and throughout treatment on SM-88 as compared to those who experienced local radiographic progression (3/23). According to the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, patients generally reported stable cognitive and sexual function domain measures, with no detectable worsening in any domain. Patient weight, EKG QTc, glucose and hematocrit and other measures, which are often side effects of ADT, did not appear affected while receiving SM-88.
The SM-88 therapy was well tolerated in all patients. There were no treatment-related serious adverse events. No adverse events resulted in dose delay, discontinuation, or reduction. The majority of Grade 1 AEs possibly or probably related to the SM-88 investigational therapy were gastrointestinal in nature.
The Phase II prostate cancer trial results are from an investigational study. SM-88 is not approved for the treatment of patients with any disease condition.
About Advanced Prostate Cancer
Time 25214
Prostate cancer is the most common malignancy in men, accounting for approximately 31,620 deaths in the United States in 2019.1 Approximately 15% of men with prostate cancer present with metastatic disease, and 20% to 30% of men with localized disease treated with definitive local therapy subsequently develop metastatic disease. While the vast majority of patients with metastatic disease demonstrate a transient response to androgen deprivation, eventually all patients develop hormone refractory prostate cancer (HRPC) and virtually all prostate cancer deaths are due to the development of metastatic HRPC.2 While chemotherapy regimens have shown a modest survival advantage in HRPC patients, median survival remains approximately 19 months,3,4 and not all patients are candidates for chemotherapy. Novel agents and new approaches such as oral cancer metabolic-based therapies are needed.
About SM-88
SM-88 is an oral investigational modified proprietary tyrosine derivative that is believed to interrupt the metabolic processes of cancer cells by breaking down the cells’ key defenses and leading to cell death through oxidative stress and exposure to the body’s natural immune system. Clinical trial data have shown that SM-88 has demonstrated encouraging tumor responses across 15 different cancers, including pancreatic, lung, breast, prostate and sarcoma cancers with minimal serious grade 3 or higher adverse events. SM-88 is an investigational therapy that is not approved for any indication in any disease. Learn more.
About Tyme Technologies
Tyme Technologies, Inc., is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s cancer metabolism-based approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system. For more information, visit www.tymeinc.com. Follow us on social media: @tyme_Inc, LinkedIn, Instagram, Facebook and YouTube.
Forward-Looking Statements/Disclosure Notice Vmware fusion 8 5 5 download free.
In addition to historical information, this press release contains forward-looking statements under the Private Securities Litigation Reform Act that involve substantial risks and uncertainties. Such forward-looking statements within this press release include, without limitation, statements regarding our drug candidates, including SM-88 and TYME-18, and their clinical potential and non-toxic safety profiles, our drug development plans and strategies, ongoing and planned preclinical and clinical trials, including the proposed TYME-19 proof-of-concept study, preliminary data results and the therapeutic design and mechanisms of our drug candidates; and readers can identify forward-looking statements by sentences or passages involving the use of terms such as “believes,” “expects,” “hopes,” “may,” “will,” “plan,” “intends,” “estimates,” “could,” “should,” “would,” “continue,” “seeks,” or “anticipates,” and similar words including their use in the negative or by discussions of future matters such as effect of the novel coronavirus (COVID-19) pandemic and the associated economic downturn and impacts on the Company's ongoing clinical trials and ability to analyze data from those trials, the cost of development and potential commercialization of our lead drug candidate and of other new products, expected releases of interim or final data from our clinical trials, possible collaborations, the timing, scope and objectives of our ongoing and planned clinical trials and other statements that are not historical. The forward-looking statements contained in this press release are based on management’s current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of TYME’s control. These statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any historical results and future results, performances or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the severity, duration, and economic impact of the COVID-19 pandemic; that the information is of a preliminary nature and may be subject to change; uncertainties inherent in the cost and outcomes of research and development, including the cost and availability of acceptable-quality clinical supply and the ability to achieve adequate clinical study design and start and completion dates; the possibility of unfavorable study results, including unfavorable new clinical data and additional analyses of existing data; risks associated with early, initial data, including the risk that the final data from any clinical trial may differ from prior or preliminary study data; final results of additional clinical trials that may be different from the preliminary data analysis and may not support further clinical development; that past reported data are not necessarily predictive of future patient or clinical data outcomes; whether and when any applications or other submissions for SM-88 may be filed with regulatory authorities; whether and when regulatory authorities may approve any applications or submissions; decisions by regulatory authorities regarding labeling and other matters that could affect commercial availability of SM-88; the ability of TYME and its collaborators to develop and realize collaborative synergies; competitive developments; and the factors described in the section captioned “Risk Factors” of TYME’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on May 22, 2020, as well as subsequent reports we file from time to time with the U.S. Securities and Exchange Commission available at www.sec.gov.
The information contained in this press release is as of its release date and TYME assumes no obligation to update forward-looking statements contained in this release as a result of future events or developments.
1https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html |
2Vogelzang N: One hundred thirteen men with prostate cancer died today. J Clin Oncol 14::1753,1996-1755 |
3Tannock IF, deWit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351::1502,2004-1512 |
4Petrylak D, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone in hormone refractory prostate cancer. N Engl J Med 351::1513,2004-1520 |
Screenshots
Description
Tyme is a simple and effective time tracking tool for anyone who wants to keep an overview of the times they have worked.
Try a free 2-week trial of the full app. After the trial, you can choose between different purchase options.
Everything at a glance.
With Tyme, everything you need is right there. An instant overview of the times you’ve worked, your budget or deadlines.
Time tracking in a team.
Do you want to track your time together? Tyme offers time tracking for teams.
Quick access & Autostart.
Control Tyme right from the Menubar, start timers via hotkeys and add notes to your time entries at any time. Tyme can also start automatically at system startup.
Dark & Light Themes
Tyme fully adopts the new macOS dark mode and has an optional light mode, if you prefer brighter colors.
Search & Archive.
Filter your projects and tasks and move completed projects or tasks to the archive. Sort them by name, due date or by your own priorities. In Tyme, your project list never gets messy.
Time tracking, Mileage tracking and Expenses.
Besides tracking time, Tyme can keep track of mileage and expenses.
Multiple timers.
If you need to have more than one active timer, start as many as you want.
Multiple time tracking modes:
Whether you are interested in when exactly you started or stopped working on a task or just need to know how many hours you’ve spent, Tyme covers it both.
Billing.
Tyme can keep track of already billed periods. No more double billing.
Statistics.
Use the statistics to monitor your workload, your working times, how often you took a break and what your average day looks like. The statistics also offer a forecast of your workload for the next weeks. Besides daily, weekly, monthly, annual time frames, you can also choose custom ranges.
Cloud Sync.
Tyme can sync your data across all your devices.
Calendar Sync.
All recorded times can be synced as events to your calendar. You can rearrange events in the calendar and edit notes. Tyme will sync back to your calendar.
Reminder.
Forgot to start a timer? It's the middle of the night and a timer is still running? Do you have deadline closing in or you're about to exceed your planned budget? Tyme can remind you of these things. No need to configure your working times. Tyme learns your habits and will remind you at the exact right time.
Export & Scripting.
Generate time sheets as PDF, export your data as CSV or JSON to use it in other applications or use AppleScript to connect to the workflows of other apps. You can also export the whole database as a backup file.
Plugins.
Your time entries can be exported to GrandTotal.
Various Import Formats.
Import your data from Tyme backups, CSV files, mite or via AppleScript.
Keyboard control.
Tyme can be used without a mouse and has keyboard shortcuts for almost all actions.
Mobile App.
With the Tyme iOS app, you can track your time, mileage and fixed costs on the go. It also offers geofencing - No need to manually start or stop a timer; it can be done automatically based on your location.
Tyme for iOS is available as a separate purchase.
— Legal —
Team Tyme: The subscription is charged monthly. The price is based on the number of users in the team and displayed in Tyme at the time of purchase. Each subscription can be terminated at any time. Subscriptions are debited from your iTunes account. Subscriptions renew automatically if automatic renewal is not disabled at least 24 hours before the end of the current subscription period. Your iTunes account will be charged for renewing your subscription 24 hours before the current subscription period expires. Subscriptions can be managed and cancelled in your account settings. As soon as you subscribe, the free trial version expires.
Privacy Policy: https://www.tyme-app.com/en/privacy-app/
Terms of Use: https://www.tyme-app.com/en/terms-of-use/
Try a free 2-week trial of the full app. After the trial, you can choose between different purchase options.
Everything at a glance.
With Tyme, everything you need is right there. An instant overview of the times you’ve worked, your budget or deadlines.
Time tracking in a team.
Do you want to track your time together? Tyme offers time tracking for teams.
Quick access & Autostart.
Control Tyme right from the Menubar, start timers via hotkeys and add notes to your time entries at any time. Tyme can also start automatically at system startup.
Dark & Light Themes
Tyme fully adopts the new macOS dark mode and has an optional light mode, if you prefer brighter colors.
Search & Archive.
Filter your projects and tasks and move completed projects or tasks to the archive. Sort them by name, due date or by your own priorities. In Tyme, your project list never gets messy.
Time tracking, Mileage tracking and Expenses.
Besides tracking time, Tyme can keep track of mileage and expenses.
Multiple timers.
If you need to have more than one active timer, start as many as you want.
Multiple time tracking modes:
Whether you are interested in when exactly you started or stopped working on a task or just need to know how many hours you’ve spent, Tyme covers it both.
Billing.
Tyme can keep track of already billed periods. No more double billing.
Statistics.
Use the statistics to monitor your workload, your working times, how often you took a break and what your average day looks like. The statistics also offer a forecast of your workload for the next weeks. Besides daily, weekly, monthly, annual time frames, you can also choose custom ranges.
Cloud Sync.
Tyme can sync your data across all your devices.
Calendar Sync.
All recorded times can be synced as events to your calendar. You can rearrange events in the calendar and edit notes. Tyme will sync back to your calendar.
Reminder.
Forgot to start a timer? It's the middle of the night and a timer is still running? Do you have deadline closing in or you're about to exceed your planned budget? Tyme can remind you of these things. No need to configure your working times. Tyme learns your habits and will remind you at the exact right time.
Export & Scripting.
Generate time sheets as PDF, export your data as CSV or JSON to use it in other applications or use AppleScript to connect to the workflows of other apps. You can also export the whole database as a backup file.
Plugins.
Your time entries can be exported to GrandTotal.
Various Import Formats.
Import your data from Tyme backups, CSV files, mite or via AppleScript.
Keyboard control.
Tyme can be used without a mouse and has keyboard shortcuts for almost all actions.
Mobile App.
With the Tyme iOS app, you can track your time, mileage and fixed costs on the go. It also offers geofencing - No need to manually start or stop a timer; it can be done automatically based on your location.
Tyme for iOS is available as a separate purchase.
— Legal —
Team Tyme: The subscription is charged monthly. The price is based on the number of users in the team and displayed in Tyme at the time of purchase. Each subscription can be terminated at any time. Subscriptions are debited from your iTunes account. Subscriptions renew automatically if automatic renewal is not disabled at least 24 hours before the end of the current subscription period. Your iTunes account will be charged for renewing your subscription 24 hours before the current subscription period expires. Subscriptions can be managed and cancelled in your account settings. As soon as you subscribe, the free trial version expires.
Privacy Policy: https://www.tyme-app.com/en/privacy-app/
Terms of Use: https://www.tyme-app.com/en/terms-of-use/
Tyme 2 5 2 Player Games
What’s New
- Fixed a small issue regarding the click area of empty cells
2 Ratings
Information
macOS 10.12 or later, 64-bit processor
- Team Tyme 1 UserR59.99
- Team Tyme 4 UserR239.99
- Single User LicenseR569.99
Time 252901
Supports
Tyme 2 5 24
Family Sharing
Up to six family members will be able to use this app with Family Sharing enabled.